TruScreen widens annual loss but upbeat about FY18 revenue

TruScreen widens annual loss but upbeat about FY18 revenue
Rebecca Howard
By Rebecca Howard June 14 (BusinessDesk) - TruScreen, the NZAX-listed cervical cancer test developer, widened its annual loss on increased costs but said it expects revenue to grow "significantly faster" than expenses in the current financial year.  The Auckland-based company reported a net loss of $3.5 million in the year ended March 31, compared to a loss $1.3 million a year earlier. Sales revenue increased 24 percent to $585,388 as it lifted production of its second generation TruScreen2 device in April 2016, and from initial sales...